REMUS — Remus Pharmaceuticals Balance Sheet
0.000.00%
- IN₹9.44bn
- IN₹9.66bn
- IN₹6.20bn
- 57
- 18
- 19
- 18
Annual balance sheet for Remus Pharmaceuticals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | PROSPECTUS | ARS | ARS | ARS |
Standards: | IAS | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 8.3 | 11.5 | 30.4 | 293 | 246 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 55.2 | 49.6 | 80.2 | 1,375 | 1,412 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 75 | 76.9 | 113 | 2,097 | 2,214 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 3.92 | 3.08 | 25.1 | 22.8 | 68.3 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 110 | 159 | 347 | 2,573 | 4,326 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 76.9 | 92 | 81.6 | 1,495 | 1,215 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 80 | 94.8 | 155 | 1,704 | 1,768 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 30.5 | 64.3 | 191 | 869 | 2,559 |
Total Liabilities & Shareholders' Equity | 110 | 159 | 347 | 2,573 | 4,326 |
Total Common Shares Outstanding |